198 related articles for article (PubMed ID: 21541674)
1. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in preoperative serum as independent prognostic markers in patients with colorectal cancer.
Dragutinović VV; Radonjić NV; Petronijević ND; Tatić SB; Dimitrijević IB; Radovanović NS; Krivokapić ZV
Mol Cell Biochem; 2011 Sep; 355(1-2):173-8. PubMed ID: 21541674
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of matrix metalloproteinase-2 and -9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers.
Emara M; Cheung PY; Grabowski K; Sawicki G; Wozniak M
Clin Chem Lab Med; 2009; 47(8):993-1000. PubMed ID: 19569980
[TBL] [Abstract][Full Text] [Related]
3. Carcinoembryonic antigen and matrix metalloproteinase 2 serum and peritoneal washes concentration in staging and prognosis in colorectal cancer patients.
Guzel T; Mirowska-Guzel D; Lech G; Wroński M; Iwanowska M; Słodkowski M
Pol Przegl Chir; 2018 Jun; 90(5):36-43. PubMed ID: 30426942
[TBL] [Abstract][Full Text] [Related]
4. High Expression of MMP-9 in Primary Tumors and High Preoperative MPO in Serum Predict Improved Prognosis in Colorectal Cancer with Operable Liver Metastases.
Peltonen R; Hagström J; Tervahartiala T; Sorsa T; Haglund C; Isoniemi H
Oncology; 2021; 99(3):144-160. PubMed ID: 33027796
[TBL] [Abstract][Full Text] [Related]
5. The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis.
Dranka-Bojarowska D; Lewinski A; Lekstan A; Gajda M; Ciosek J; Mrowiec S
J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571962
[TBL] [Abstract][Full Text] [Related]
6. The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
Barabás L; Hritz I; István G; Tulassay Z; Herszényi L
Dig Dis; 2021; 39(3):217-224. PubMed ID: 32961536
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients.
Waas ET; Hendriks T; Lomme RM; Wobbes T
Dis Colon Rectum; 2005 Apr; 48(4):700-10. PubMed ID: 15906450
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the value of preoperative serum levels of CA 242 and CEA in the staging and postoperative survival of colorectal adenocarcinoma patients.
Kim SB; Fernandes LC; Saad SS; Matos D
Int J Biol Markers; 2003; 18(3):182-7. PubMed ID: 14535588
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinases 2, 7 and 9 in patients with colorectal cancer.
Kostova E; Slaninka-Miceska M; Labacevski N; Jakovski K; Trojachanec J; Atanasovska E; Janevski V; Jovanovik R; Janevska V
Vojnosanit Pregl; 2014 Jan; 71(1):52-9. PubMed ID: 24516991
[TBL] [Abstract][Full Text] [Related]
11. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients.
Mroczko B; Groblewska M; Okulczyk B; Kedra B; Szmitkowski M
Int J Colorectal Dis; 2010 Oct; 25(10):1177-84. PubMed ID: 20556397
[TBL] [Abstract][Full Text] [Related]
13. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer.
Knychalski B; Lukieńczuk T
Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.
Kushlinskii NE; Gershtein ES; Ivannikov AA; Davydov MM; Chang VL; Ognerubov NA; Stilidi IS
Bull Exp Biol Med; 2019 Jan; 166(3):373-376. PubMed ID: 30627896
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic values of MMP-7, MMP-9, MMP-11, TIMP-1, TIMP-2, CEA, and CA19-9 in patients with colorectal cancer.
Huang X; Lan Y; Li E; Li J; Deng Q; Deng X
J Int Med Res; 2021 May; 49(5):3000605211012570. PubMed ID: 33942633
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients.
Groblewska M; Mroczko B; Gryko M; Kędra B; Szmitkowski M
Folia Histochem Cytobiol; 2010 Dec; 48(4):564-71. PubMed ID: 21478099
[TBL] [Abstract][Full Text] [Related]
17. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of postoperative serum carcinoembryonic antigen levels in colorectal cancer patients who smoke.
Huang CS; Chen CY; Huang LK; Wang WS; Yang SH
PLoS One; 2020; 15(6):e0233687. PubMed ID: 32502149
[TBL] [Abstract][Full Text] [Related]
19. [The pre- and postoperative monitoring of the immunological indices and tumor markers in colorectal carcinoma].
Iarŭmov N; Ignatov A; Viiachki I
Khirurgiia (Sofiia); 1998; 51(3):42-8. PubMed ID: 9974027
[TBL] [Abstract][Full Text] [Related]
20. Plasma gelatinase activity does not reflect disease activity after operation for colorectal cancer.
Waas ET; Wobbes T; Lomme RM; Hendriks T
Oncology; 2005; 68(2-3):256-62. PubMed ID: 16015042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
